Physician profile
Peter Karth
NPI 1508181355
$118,733.59
in general payments reported to CMS, 2019-2025
19 companies · $2,547 in 2025
The $2,547 reported for 2025 was more than what 84% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $23K · 2021: $86.69 · 2022: $56K · 2023: $3,977 · 2024: $6,116 · 2025: $2,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $2,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,202.50 |
| Food and Beverage | $2,438.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $47,585.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $33,961.03 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $12,329.81 | 2019-2025 | Vabysmo, Susvimo |
| Carl Zeiss Meditec, INC. | $8,000.00 | 2019 | |
| Alcon Vision LLC | $5,697.14 | 2020-2024 | Constellation |
| Topcon Healthcare Solutions, INC. | $5,000.00 | 2020 | |
| Genentech, INC. | $3,206.70 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $1,627.28 | 2024-2025 | Syfovre |
| Abbvie INC. | $505.87 | 2023-2025 | |
| Astellas Pharma US INC | $180.43 | 2024-2025 | Izervay |
| Welch Allyn | $150.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $133.75 | 2019-2020 | |
| Glaukos Corporation | $121.30 | 2024 | Idose |
| Heidelberg Engineering, INC. | $93.69 | 2025 | Spectralis |
| Allergan, INC. | $38.55 | 2020-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $37.25 | 2025 | Iluvien, Yutiq |
| Alimera Sciences, INC. | $24.68 | 2024 | Iluvien, Yutiq |
| Kala Pharmaceuticals, INC. | $23.71 | 2019 | |
| Lumibird Medical INC. | $17.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Karth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.